What was recalled
This page synthesizes the sourcing and clinical-veterinary framework around cobalamin in commercial pet food. Cobalamin is the only B-vitamin not synthesizable by plants or animals; it is produced exclusively by certain bacteria and archaea, primarily anaerobic species. Mammalian cobalamin requirement is met through dietary intake of animal tissue (where bacterially synthesized cobalamin has been concentrated through the food chain), through ingestion of cobalamin-containing microorganisms (in ruminants, via rumen microflora; in monogastric animals, only modestly via colonic microflora producing cobalamin too distal for efficient absorption), or through synthetic supplementation. The two essential enzymatic functions are methionine synthase (converts homocysteine to methionine using methylcobalamin and 5-methyltetrahydrofolate; this reaction is central to the methylation economy and folate cycle) and methylmalonyl-CoA mutase (converts methylmalonyl-CoA to succinyl-CoA using adenosylcobalamin; required for propionate metabolism, branched-chain amino acid catabolism, and odd-chain fatty acid oxidation).
Commercial pet food cobalamin sources fall into three categories. Cyanocobalamin is the most shelf-stable synthetic form and dominates the global vitamin supplement market by volume; cyanocobalamin must be metabolically activated in vivo by removal of the cyanide moiety and conversion to methylcobalamin or adenosylcobalamin. The cyanide moiety is biologically negligible at typical supplementation doses. Methylcobalamin and hydroxocobalamin are bioactive forms with somewhat lower shelf stability; methylcobalamin is the cofactor form for methionine synthase and is increasingly used in human supplementation, while hydroxocobalamin dominates injectable veterinary therapy for cobalamin deficiency. Adenosylcobalamin is the cofactor form for methylmalonyl-CoA mutase and is occasionally used in supplementation. Animal tissue (liver, kidney, muscle meat, fish) contributes pre-formed bioactive cobalamin to named-meat-anchored commercial pet food.
Why it was recalled
The structural controversy has three layers. Layer one — vegan pet food carnivore-specificity: cobalamin is the most carnivore-specific essential vitamin because no plant-source food contains biologically active B12 in nutritionally meaningful quantities. Algae, fermented foods, and yeast biomass contain B12 analogs (some inactive, some partially active) that do not reliably substitute for animal-source cobalamin. Vegan dog and cat formulations therefore require synthetic cobalamin supplementation; oversight by a board-certified veterinary nutritionist (DACVN) is essential to verify supplementation adequacy. The carnivore specificity is part of the broader feline obligate-carnivore framework and applies meaningfully to canine vegan formulation as well.
Layer two — chronic enteropathy cobalamin malabsorption: cobalamin absorption is uniquely complex among vitamins. Dietary cobalamin is released from food protein by gastric acid and pepsin, bound first by haptocorrin (R-protein) in the stomach, transferred to intrinsic factor in the duodenum, and absorbed by specific receptor-mediated endocytosis in the distal ileum. Each step is required for normal absorption. Cats and dogs with chronic inflammatory bowel disease (IBD), exocrine pancreatic insufficiency (EPI), small-intestinal lymphoma, severe enteritis, or ileal resection show profound cobalamin malabsorption regardless of dietary intake. The clinical syndrome (hypocobalaminemia with elevated methylmalonic acid) is common in feline IBD and EPI and is a meaningful diagnostic and therapeutic checkpoint in small-animal internal medicine. Treatment is parenteral (subcutaneous) cobalamin supplementation, typically as hydroxocobalamin or cyanocobalamin, given weekly initially and tapered to monthly maintenance. Oral cobalamin at high dose has been shown to also be effective in many cases. The clinical relevance extends well beyond formulation framework into routine veterinary care.
Layer three — methylcobalamin versus cyanocobalamin debate: human supplementation discussion increasingly favors methylcobalamin (the active cofactor form for methionine synthase) over cyanocobalamin (which must be activated in vivo). The argument is that individuals with specific methylation-pathway polymorphisms (MTHFR variants) may not efficiently convert cyanocobalamin to methylcobalamin and may benefit from pre-formed methylcobalamin supplementation. The companion-animal evidence for this distinction is limited; the clinical importance for typical dogs and cats on AAFCO-compliant commercial diet is essentially negligible. The trade-off in commercial pet food formulation is between shelf stability (cyanocobalamin highly stable, methylcobalamin sensitive to light and heat) and theoretical bioavailability advantage. Most commercial pet food uses cyanocobalamin for shelf-stability reasons; veterinary therapeutic injectable cobalamin uses hydroxocobalamin or cyanocobalamin.
Health risks for your pet
Clinical cobalamin deficiency in dogs and cats fed AAFCO-compliant commercial diets is rare at the population level but disproportionately concentrated in cats and dogs with chronic enteropathies (IBD, EPI, small-intestinal lymphoma, severe enteritis). The hypocobalaminemia syndrome in chronic enteropathy patients is well-characterized: depleted serum cobalamin, elevated methylmalonic acid (functional B12 deficiency marker), and clinical signs overlapping with the underlying intestinal disease (weight loss, anorexia, vomiting, diarrhea, anemia). Untreated deficiency can produce peripheral neuropathy and degenerative central nervous system changes through methionine cycle disruption. Treatment is parenteral cobalamin supplementation (weekly subcutaneous injection initially, tapered to monthly maintenance) or oral high-dose cobalamin where shown effective. The diagnostic and therapeutic framework is established in small-animal internal medicine and surfaces routinely in chronic enteropathy management.
Cobalamin excess from dietary sources or supplementation is essentially never seen; the vitamin has an extremely wide safety margin and excess is excreted in urine. Therapeutic high-dose cobalamin (250-1,000 mcg per dose for dogs and cats) is routinely used in veterinary medicine without toxicity concerns. Cyanocobalamin contains a cyanide moiety that must be metabolized; the cyanide load at therapeutic doses is biologically trivial (a small fraction of normal dietary cyanide exposure from common foods).
What to do if you bought affected product
Pet owners can manage cobalamin adequacy through several practical approaches: (1) for most healthy pets on AAFCO-compliant commercial diet, cobalamin adequacy is not a practical concern — commercial formulation meets the requirement; (2) for cats with chronic GI symptoms (chronic vomiting, weight loss, intermittent diarrhea), discuss serum cobalamin and folate testing with your veterinarian as part of routine workup — feline IBD and EPI commonly produce hypocobalaminemia regardless of dietary intake, and supplementation is part of standard management; (3) for dogs with chronic GI disease or known EPI, regular serum cobalamin monitoring is appropriate; parenteral or oral high-dose supplementation per veterinary protocol; (4) for vegan dog and cat formulations, verify the formulation includes synthetic cobalamin supplementation and has been balanced by a board-certified veterinary nutritionist (DACVN); plant sources do not provide biologically active B12; (5) do not assume oral B-complex supplementation will resolve hypocobalaminemia in chronic enteropathy patients — the underlying malabsorption requires either parenteral supplementation bypassing the GI tract or high-dose oral cobalamin under veterinary monitoring; (6) watch for neurologic signs in older pets — peripheral neuropathy, cognitive change, ataxia have multiple causes including potentially undiagnosed cobalamin deficiency; serum cobalamin is a reasonable component of geriatric workup.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate cobalamin source form per our published methodology, since AAFCO-compliant commercial diets meet the canine and feline requirements through standard cyanocobalamin supplementation plus animal-tissue contributions. The structural concern is concentrated in the chronic enteropathy clinical-population framework (well-addressed by veterinary management) and in vegan formulation contexts (requiring DACVN oversight). Future rubric extension under consideration: vegan dog and cat formulations would be evaluated against documented synthetic cobalamin supplementation and veterinary nutritionist balance; named-meat-anchored and organ-meat-inclusive formulations would receive scoring credit reflecting pre-formed cobalamin contribution. The broader category effect is modest; cobalamin is a structurally well-addressed B-vitamin in commercial-fed populations at the formulation level.